US Stock MarketDetailed Quotes
ADXN Addex Therapeutics
- 11.0800
- +0.1200+1.09%
Close Nov 5 16:00 ET
11.84MMarket Cap0.00P/E (TTM)
11.7000High10.4000Low123.04KVolume11.2600Open10.9600Pre Close1.36MTurnover23.00%Turnover RatioLossP/E (Static)1.07MShares27.900052wk High0.81P/B5.93MFloat Cap5.000052wk Low--Dividend TTM534.90KShs Float750.4000Historical High--Div YieldTTM11.86%Amplitude5.0000Historical Low11.0760Avg Price1Lot Size
About Addex Therapeutics Company
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
Company Profile
SymbolADXN
Company NameAddex Therapeutics
Listing DateJan 29, 2020
Founded2002
CEOMr. Tim Dyer
MarketNASDAQ
Employees23
Securities TypeDR
ADS Ratio1.0 : 120.0
Fiscal Year Ends12-31
Address9, Chemin des Mines,Plan-les-Ouates
CityGeneva
ProvinceGeneve (Geneva)
CountrySwitzerland
Zip Code1202
Phone41-22-884-15-55
Company Executives
- Name
- Position
- Salary
- Tim Dyer
- Chief Executive Officer and Director
- --
- Dr. Roger M. Mills,M.D.
- Chief Medical Officer and Director
- --
- Vincent Lawton
- Chairman of the Board
- 155.75K
- Raymond Hill
- Director
- 89.65K
- Jake R. Nunn
- Independent Director
- 41.29K
- Dr. Isaac Manke
- Independent Director
- 41.29K
- Robert Lütjens
- Head of Discovery, Biology
- --
- Lénaic Teyssédou
- Head of Finance
- --
- Jean-Philippe Rocher
- Head of Discovery, Chemistry
- --
- Dr. Mikhail Kalinichev
- Head of Translational Science
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data